News and Breakthroughs
Find the latest news and discoveries, as well highlights from Lurie Cancer Center’s programs and events through the links below. To learn more about our accomplishments and the people who make them possible, visit the article archive for older news and read our 2020 Year in Review.
Visit our gallery to view a wide range of photos and videos for oncology professionals, cancer patients and families, cancer survivors, caregivers and community members.
Combining a new hormone therapy drug with chemotherapy and another hormone therapy increased overall survival in patients with high-volume and both high-risk and low-risk metastatic hormone-sensitive prostate cancer, according to a post hoc analysis published in the Journal of Clinical Oncology.
Northwestern Medicine scientists have identified a new compound which could inform future HIV cure strategies, according to research published in Science Advances.
On Sunday, June 4, Lurie Cancer Center and Northwestern Medicine will welcome cancer survivors and supporters back to Grant Park for our 30th Annual Cancer Survivors’ Celebration Walk & 5K!
Northwestern Medicine scientists have developed a new tool to predict the risk of venous thromboembolism in patients with adult-type diffuse gliomas.
Northwestern Medicine scientists have uncovered a mechanism by which exercise activates metabolic benefits in the body, according to a new study published in Cell Metabolism.
During these extraordinary times, we need exceptional people to blaze new trails -- pushing the boundaries of scientific discovery, moving innovations into the clinical setting, sharing vital cancer education and services in the larger community, and providing the highest level of compassionate care to our patients and families across Northwestern Medicine.
People with sickle cell disease who receive nonmyeloablative stem cell transplants are at greater risk for developing new tumors, according to a new study published in the Journal of Clinical Oncology.
Get to know Lurie Cancer Center member, Kehinde Adekola, MD, MS. Dr. Adekola, associate professor in the Division of Hematology and Oncolog and co-chair of the Diversity and Cultural Affairs Council (DCAC) of the Department of Medicine at Northwestern University Feinberg School of Medicine, was featured in the latest issue of Northwestern Medicine’s “Diversity, Equity & Inclusion Quarterly.”
The Lurie Cancer Center is pleased to welcome Lucy A. Godley, MD, PhD, as the inaugural director of the Jeff and Marianne Silver Family Blood Cancer Institute of the Robert H. Lurie Comprehensive Cancer Center, effective April 1, 2023. She will also serve as Clinical Director of Cancer Genetics.
Northwestern Medicine scientists have identified a gene that plays a role in cellular responses to molecular stressors, such as DNA damage and nutrient scarcity.
Oral vitamin D supplements reduced skin inflammation and increased immunoprotection in patients with chemical skin injuries, according to findings from a recent Northwestern Medicine clinical trial.
Investigators have discovered that a specific complex drives cell proliferation in mutated myeloproliferative neoplasms, suggesting this complex could serve as an ideal therapeutic target, according to a recent Northwestern medicine study.
As we pay tribute to the leaders who have challenged us all to work intentionally in pursuit of equity and justice, Black History Month serves as a great opportunity to learn from their legacy. Lurie Cancer Center is committed to creating an inclusive space for meaningful conversations, with the resources and support to act on them.
A new way to significantly increase the potency of almost any vaccine has been developed by Northwestern scientists.
Northwestern Medicine investigators have discovered that specific calcium channels help regulate sex differences in the functioning of immune cells for neuroinflammation and overall neuropathic pain.
Scientists have identified a new cell type implicated in the development of medulloblastoma, according to a study published in Nature.
Targeting cellular post-transcription mechanisms in the CD73 ectoenzyme may promote anti-tumor immunity and slow cancer progression in triple-negative breast cancer, according to a recent Northwestern Medicine study.
The National Comprehensive Cancer Network’s new Diversity, Equity, & Inclusion (DEI) Directors Forum is working to improve diversity of clinical staff representation across the nation’s leading academic cancer centers. June McKoy, MD, MPH, JD, MBA, assistant director of Diversity, Equity, and Inclusion at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, has been selected to join the forum.
High doses of vitamin D alleviated symptoms for patients with toxic erythema of chemotherapy significantly faster than current treatments, according to a recent study.
We are pleased to announce that Sofia Garcia, PhD, has been named director of the Cancer Survivorship Institute of the Lurie Cancer Center, effective January 1, 2023.
On Monday, January 16, we honor the life and legacy of Dr. Martin Luther King Jr. The Northwestern community will celebrate Dr. King with an expanded special commemoration to inspire reflection and keep the dream alive.
Patients with relapsed or refractory hairy cell leukemia who were treated with vemurafenib experienced excellent response and relapse-free survival, according to a recent clinical trial published in Blood.
Northwestern Medicine investigators have revealed new insights into how cell type switches facilitate tumor growth and treatment resistance in small cell lung cancer, according to findings published in Science Advances.
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University is pleased to announce that Mario Shields, PhD, a research assistant professor of Medicine in the Division of Hematology and Oncology, has received the first Diversity Scholars Award.
The Lurie Cancer Center is pleased to announce IDP Research Innovation Challenge Award recipients for 2023.
Patient-reported outcomes in relapsed or refractory large B-cell lymphoma revealed that receiving CAR T-cell immunotherapy was associated with higher quality of life, according to a recent study.
A Northwestern Medicine study has discovered that elevated PALI1 in advanced prostate tumors mediates crosstalk between two primary epigenetic silencing mechanisms, suggesting that dual epigenetic inhibition may be an effective therapeutic strategy.
Investigators have developed a novel personalized T-cell therapy approach that may identify specific targets unique to a patient’s cancer cells more effectively than current treatments, according to findings published in Nature.
Northwestern Medicine scientists have identified a new therapeutic target against tumor cells and developed a compound which slows tumor growth and bolsters immune response.
See more news in the article archive.